Center for Immunology of Emerging Infectious Diseases

新发传染病免疫学中心

基本信息

批准号：
7936201
负责人：
DONALD SCOTT BURKE
金额：
$ 64.99万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-28 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7936201
关键词：
Center Immunology Emerging Infectious Diseases

项目摘要

Dengue virus (DENV) infections of humans has steadily increased in importance as an emerging infectious disease, and the development of protective vaccines to DENV disease has been impeded by a lack of understanding of the specificity of virus-specific immune responses and their role in protection and disease. To address these critical issues related to DENV infection and disease, we have established a unique collaborative research consortium, US-Brazil Center for Immunology of Emerging Infectious Diseases (CIEID) that includes investigators from the University of Pittsburgh, Johns Hopkins School of Medicine, and the Laboratory of Virology and Experimental Therapy in Recife, Brazil. The focus of the CIEID is to conduct a comprehensive analysis of the immune responses to DENV infection of humans using the unique clinical samples obtained from the Clinical Core in Brazil to characterize the initial role of antigen presenting cells in DENV immunopathogenesis (Project 1), to define the interaction of T-lymphocyte with dendritic cells in the progression of immunity and disease (Project 2), to define how DENV suppresses innate immune responses to DENV infection (Project 3), and to define the specificity of common T-lymphocyte responses that are established to DENV infection. These translational immunology studies are complemented by a Technology Development Project designed to identify reliable biomarkers of DENV disease (Project 5), by a Pilot Projects Core to recruit new research areas and expertise, by a Virology Core to provide viral and molecular reagents, and by an Adminstrative Core to coordinate project activities and interactions with the CCHI Network Steering Committee. It is anticipated that the results of the proposed studies will produce important new insights into the role of DENV-specific immunity in infection and disease that can then inform strategies for treatment and vaccine development. In addition, it is expected that the US-Brazil CIEID will provide platform technologies and comprehensive expertise in translational immunology that can readily be applied to other emerging infections diseases or biodefense pathogens.

作为一种新兴传染病，人类感染登革热病毒 (DENV) 的重要性稳步上升 DENV 疾病的保护性疫苗的开发因缺乏了解病毒特异性免疫反应的特异性及其在保护和疾病中的作用。到为了解决这些与 DENV 感染和疾病相关的关键问题，我们建立了一个独特的合作机制研究联盟，美国-巴西新发传染病免疫学中心 (CIEID)，其中包括来自匹兹堡大学、约翰霍普金斯大学医学院和实验室的研究人员巴西累西腓的病毒学和实验治疗。 CIEID 的重点是开展全面的使用从以下来源获得的独特临床样本分析人类对 DENV 感染的免疫反应巴西临床核心表征抗原呈递细胞在 DENV 中的初始作用免疫发病机制（项目 1），定义 T 淋巴细胞与树突状细胞的相互作用免疫和疾病的进展（项目 2），以确定 DENV 如何抑制先天免疫反应 DENV 感染（项目 3），并定义已建立的常见 T 淋巴细胞反应的特异性登革热病毒感染。这些转化免疫学研究得到了技术开发的补充旨在识别 DENV 疾病可靠生物标志物的项目（项目 5），由试点项目核心招募新的研究领域和专业知识，由病毒学核心提供病毒和分子试剂，并由管理核心负责协调项目活动以及与 CCHI 网络指导委员会的互动。预计所提出的研究结果将对以下方面的作用产生重要的新见解：感染和疾病中的登革热病毒特异性免疫可以为治疗和疫苗策略提供信息发展。此外，预计美巴CIEID将提供平台技术和转化免疫学方面的全面专业知识，可轻松应用于其他新出现的感染疾病或生物防御病原体。